Ilika boosts battery plans with new fundraise

Ilika PLC (IKA) plans to raise up to £3.5 million, including a £500,000 retail offer, to bolster its Stereax and Goliath battery technologies. £1.1 million will support the final tech transfer and commercialization of Stereax with Cirtec Medical, which is progressing with initial production. The remaining funds will advance Ilika's Goliath program, specifically scaling up to 10Ah solid-state battery prototypes, five times larger than previous versions, for more meaningful commercial testing and customer validation.

Analysis

Ilika PLC is undertaking a strategic fundraise of up to £3.5 million, inclusive of a £500,000 retail offer, to accelerate the development and commercialization of its key battery technologies, Stereax and Goliath. Approximately £1.1 million of the proceeds are earmarked for the Stereax program, specifically to support the final phase of technology transfer to its licensing partner, Cirtec Medical, and to facilitate initial commercialization efforts, including testing, validation, and customer support. Cirtec Medical is reportedly making significant progress, with initial production batches of Stereax batteries underway at its Lowell, Massachusetts facility, and has presented optimistic views on future commercial applications. The balance of the funds, approximately £2.4 million, will be channeled into the Goliath solid-state battery program, focusing on the design, build, and testing of its P1.5 prototype, notably scaling up to 10Ah batteries—a fivefold increase in capacity from the previous 2Ah prototypes. This advancement is critical for enabling more meaningful commercial testing and customer validation, moving Ilika closer to larger-scale evaluation by potential customers. The fundraising initiative, described by CEO Graeme Purdy as a "financial shot in the arm," is designed to maintain momentum across both platforms, underpinning ongoing customer engagement and validation processes, reflecting an optimistic outlook for the company's technological advancements.

Key Decisions for Investors

• Investors should closely monitor Ilika's execution on the Stereax technology transfer to Cirtec Medical and the subsequent commercial ramp-up, as these represent key milestones for near-term value realization.
• The successful development, testing, and customer validation of the larger 10Ah Goliath prototypes will be a critical indicator of Ilika's capability to scale its solid-state battery technology for commercially significant applications.
• While the £3.5 million fundraise is crucial for advancing these strategic development programs, investors should consider the terms of the capital raise and its potential dilutive impact, particularly for an AIM-listed company, against the backdrop of enhanced technological and commercial prospects.